Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
NCT ID: NCT00891124
Last Updated: 2009-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4045 participants
OBSERVATIONAL
2009-05-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
NCT00925717
Korea National Diabetes Program
NCT01212198
The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program
NCT03503942
Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
NCT01154244
Developement of Questionnaire to Evaluate a Regularity of Lifestyle in Type 2 Diabetic Patients
NCT00455988
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Type II DM and Hypertension and/or Hyperlipidemia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with hypertension and / or hyperlipidemia
* Patients who had agreed to Informed
Exclusion Criteria
* Patients with neither hypertension and hyperlipidemia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joonwoo Bahn
Role: STUDY_DIRECTOR
ASTRAZENECA, Korea Medical Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Busan, , South Korea
Research Site
Cheiju, , South Korea
Research SIte
Daegu, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Hongseong, , South Korea
Research Site
Seoul, , South Korea
Research Site
Sungman, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CKR-DUM-2009/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.